Matthias Titeux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1142390/publications.pdf

Version: 2024-02-01

41	2,485	279778	330122
papers	citations	23 h-index	37 g-index

43	43	43	3883
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TLR3 Deficiency in Patients with Herpes Simplex Encephalitis. Science, 2007, 317, 1522-1527.	12.6	970
2	Induced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2011, 131, 848-856.	0.7	139
3	A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity. Science Immunology, 2018, 3, .	11.9	132
4	SIN Retroviral Vectors Expressing COL7A1 Under Human Promoters for Ex Vivo Gene Therapy of Recessive Dystrophic Epidermolysis Bullosa. Molecular Therapy, 2010, 18, 1509-1518.	8.2	94
5	A frequent functional SNP in theMMP1promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. Human Mutation, 2008, 29, 267-276.	2.5	93
6	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Science Translational Medicine, 2018, 10, .	12.4	91
7	Human Fibroblasts Share Immunosuppressive Properties with Bone Marrow Mesenchymal Stem Cells. Journal of Clinical Immunology, 2010, 30, 607-619.	3.8	79
8	Human synemin gene generates splice variants encoding two distinct intermediate filament proteins. FEBS Journal, 2001, 268, 6435-6449.	0.2	74
9	Human Keratinocytes Acquire Cellular Cytotoxicity under UV-B Irradiation. Journal of Biological Chemistry, 2006, 281, 13525-13532.	3.4	73
10	Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARÂ in cell invasion process. Carcinogenesis, 2003, 24, 1325-1336.	2.8	61
11	DNA-Based Prenatal Diagnosis of Harlequin Ichthyosis and Characterization of ABCA12 Mutation Consequences. Journal of Investigative Dermatology, 2007, 127, 568-573.	0.7	60
12	Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an InÂVivo RDEB Model. Journal of Investigative Dermatology, 2016, 136, 2387-2395.	0.7	56
13	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight, 2019, 4, .	5.0	56
14	The mouse synemin gene encodes three intermediate filament proteins generated by alternative exon usage and different open reading frames. Experimental Cell Research, 2004, 298, 431-444.	2.6	53
15	Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 RetroviralÂVector. Journal of Investigative Dermatology, 2016, 136, 1346-1354.	0.7	44
16	Confirmation of RAX gene involvement in human anophthalmia. Clinical Genetics, 2008, 74, 392-395.	2.0	37
17	Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa. Gene Therapy, 2010, 17, 930-937.	4.5	34
18	siRNA-Mediated Allele-Specific Inhibition of Mutant Type VII Collagen in Dominant Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2012, 132, 1741-1743.	0.7	30

#	Article	IF	Citations
19	Comparison of 3 type VII collagen (C7) assays for serologic diagnosis of epidermolysis bullosa acquisita (EBA). Journal of the American Academy of Dermatology, 2016, 74, 1166-1172.	1.2	29
20	Antisense-Mediated Exon Skipping to Reframe Transcripts. Methods in Molecular Biology, 2012, 867, 221-238.	0.9	27
21	Synemin expression in developing normal and pathological human retina and lens. Experimental Neurology, 2003, 183, 499-507.	4.1	26
22	Keratitis-Ichthyosis-Deafness Syndrome Caused by GJB2 Maternal Mosaicism. Journal of Investigative Dermatology, 2009, 129, 776-779.	0.7	25
23	Generalized Epidermolytic Hyperkeratosis in Two Unrelated Children from Parents with Localized Linear Form, and Prenatal Diagnosis. Journal of Investigative Dermatology, 2006, 126, 2715-2717.	0.7	24
24	EBGene trial: patient preselection outcomes for the European GENEGRAFT exÂvivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa. British Journal of Dermatology, 2020, 182, 794-797.	1.5	19
25	HEK293-Based Production Platform for Î³-Retroviral (Self-Inactivating) Vectors: Application for Safe and Efficient Transfer ofCOL7A1cDNA. Human Gene Therapy Clinical Development, 2014, 25, 218-228.	3.1	18
26	Lens cell targetting for gene therapy of prevention of posterior capsule opacification. Gene Therapy, 2006, 13, 1422-1429.	4.5	17
27	Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 133-143.	2.4	17
28	Recessive dystrophic epidermolysis bullosa caused by COL7A1 hemizygosity and a missense mutation with complex effects on splicing. Human Mutation, 2006, 27, 291-292.	2.5	16
29	Intradermal Injection of Bone Marrow Mesenchymal Stromal Cells Corrects Recessive Dystrophic Epidermolysis BullosaÂinÂa Xenograft Model. Journal of Investigative Dermatology, 2018, 138, 2483-2486.	0.7	14
30	Epidermolysis bullosa simplexâ€“generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotypeâ€phenotype correlation and in silico modeling analysis. Pediatric Dermatology, 2019, 36, 132-138.	0.9	12
31	Differences in the activation of the GFAP gene promoter by prion and viral infections. Molecular Brain Research, 2002, 109, 119-127.	2.3	11
32	Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa. Dermatologic Clinics, 2010, 28, 361-366.	1.7	11
33	Marked intrafamilial phenotypic heterogeneity in dystrophic epidermolysis bullosa caused by inheritance of a mild dominant glycine substitution and a novel deep intronic recessiveCOL7A1mutation. British Journal of Dermatology, 2016, 174, 1122-1125.	1.5	11
34	Three Severe Cases of EBS Dowling-Meara Caused by Missense and Frameshift Mutations in the Keratin 14 Gene. Journal of Investigative Dermatology, 2006, 126, 773-776.	0.7	9
35	Emerging drugs for the treatment of epidermolysis bullosa. Expert Opinion on Emerging Drugs, 2020, 25, 467-489.	2.4	9
36	A New Case of Keratin 14 Functional Knockout Causes Severe Recessive EBS and Questions the Haploinsufficiency Model of Naegeliâ€“Franceschettiâ€“Jadassohn Syndrome. Journal of Investigative Dermatology, 2011, 131, 2131-2133.	0.7	8

#	Article	IF	Citations
37	The Molecular Revolution in Cutaneous Biology: Emerging Landscape in Genomic Dermatology: New Mechanistic Ideas, Gene Editing, and Therapeutic Breakthroughs. Journal of Investigative Dermatology, 2017, 137, e123-e129.	0.7	6
38	333 Rat hepatic stellate cells express the intermediate filament anchor protein synemin. Journal of Hepatology, 2004, 40, 101.	3.7	0
39	LB799 BAC clone modification strategy to generate a new mouse model for RDEB suitable for gene-editing. Journal of Investigative Dermatology, 2016, 136, B9.	0.7	0
40	170 Bone marrow-derived MSCs show therapeutic potential for recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology, 2016, 136, S190.	0.7	0
41	Antisense-Mediated Splice Modulation to Reframe Transcripts. Methods in Molecular Biology, 2018, 1828, 531-552.	0.9	0